Everolimus extends PFS for HR positive, HER2 negative breast cancer
Everolimus extends PFS for HR positive, HER2 negative breast cancer
TEAM IIb trial results: Adjuvant ibandronate in early breast cancer
Neoadjuvant abemaciclib for HR positive, HER negative breast cancer
TCHP with/out oestrogen for HR/HER positive breast cancer
Efficacy of veliparib with carboplatin and paclitaxel for BRCA1/2 mutations in metastatic breast cancer
Extended adjuvant endrocine therapy with letrozole after aromatase inhibition
PrECOG: Added everolimus extends PFS for HR positive, HER2 negative breast cancer
Pacritinib versus best available therapy for low platelet Myelofibrosis
Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL
ASH 2016 highlights: breaking new ground in haematology
TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients
Azacitidine plus nivolumab against acute myeloid leukaemia